These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18590464)

  • 21. Paromomycin in the treatment of leishmaniasis.
    Sundar S; Chakravarty J
    Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
    de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
    J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
    Dar MJ; Din FU; Khan GM
    Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promising therapeutic targets for antileishmanial drugs.
    Werbovetz KA
    Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in Development of New Treatment for Leishmaniasis.
    de Menezes JP; Guedes CE; Petersen AL; Fraga DB; Veras PS
    Biomed Res Int; 2015; 2015():815023. PubMed ID: 26078965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-leishmanial Nanotherapeutics: A Current Perspective.
    Shah A; Gupta SS
    Curr Drug Metab; 2019; 20(6):473-482. PubMed ID: 30360732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of new antileishmanial drugs--current knowledge and future prospects.
    Le Pape P
    J Enzyme Inhib Med Chem; 2008 Oct; 23(5):708-18. PubMed ID: 18671165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmanicidal activity of benzophenones and extracts from Garcinia brasiliensis Mart. fruits.
    Pereira IO; Marques MJ; Pavan AL; Codonho BS; Barbiéri CL; Beijo LA; Doriguetto AC; D'Martin EC; dos Santos MH
    Phytomedicine; 2010 Apr; 17(5):339-45. PubMed ID: 19762221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage specific drug delivery in experimental leishmaniasis.
    Basu MK; Lala S
    Curr Mol Med; 2004 Sep; 4(6):681-9. PubMed ID: 15357216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanomedicines for Therapy of Visceral Leishmaniasis.
    Want MY; Yadav P; Afrin F
    J Nanosci Nanotechnol; 2016 Mar; 16(3):2143-51. PubMed ID: 27455613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
    Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
    Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F; Demicheli C
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SB-83, a 2-Amino-thiophene derivative orally bioavailable candidate for the leishmaniasis treatment.
    Rodrigues KADF; Silva DKF; Serafim VL; Andrade PN; Alves AF; Tafuri WL; Batista TM; Mangueira VM; Sobral MV; Moura RO; Mendonça Junior FJB; Oliveira MR
    Biomed Pharmacother; 2018 Dec; 108():1670-1678. PubMed ID: 30372869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in leishmaniasis vaccine delivery systems.
    Bhowmick S; Ali N
    Expert Opin Drug Deliv; 2008 Jul; 5(7):789-803. PubMed ID: 18590463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redox biology of Leishmania and macrophage targeted nanoparticles for therapy.
    Sarwar HS; Akhtar S; Sohail MF; Naveed Z; Rafay M; Nadhman A; Yasinzai M; Shahnaz G
    Nanomedicine (Lond); 2017 Jul; 12(14):1713-1725. PubMed ID: 28635366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.
    Espuelas S; Plano D; Nguewa P; Font M; Palop JA; Irache JM; Sanmartín C
    Curr Med Chem; 2012; 19(25):4259-88. PubMed ID: 22834813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
    Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
    J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leishmaniasis in humans: drug or vaccine therapy?
    Ghorbani M; Farhoudi R
    Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis.
    Tyagi R; Lala S; Verma AK; Nandy AK; Mahato SB; Maitra A; Basu MK
    J Drug Target; 2005 Apr; 13(3):161-71. PubMed ID: 16036304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.